Registry for vascular cognitive impairment treatment with traditional Chinese medicine (REVIEW-TCM): Rationale and design of a prospective, observational study

Yao Xie, Le Xie, Junlin Jiang, Ting Yao, Guo Mao, Rui Fang, Fuliang Kang, Shiliang Wang, Anchao Lin, Ying Gao, Jinwen Ge, Dahua WumedRxiv 2023 · DOI

Introduction

Vascular Cognitive Impairment (VCI) represents a significant and growing public health challenge, particularly among the elderly. It encompasses a spectrum of cognitive deficits resulting from cerebrovascular disease, ranging from mild impairment to full-blown vascular dementia. In China, the burden is particularly high, with millions affected. Despite its prevalence, the pharmaceutical landscape for VCI remains limited, often relying on Western medications like cholinesterase inhibitors and memantine, which provide only modest symptomatic relief.

Traditional Chinese Medicine (TCM) has been employed for thousands of years to treat symptoms associated with dementia. While contemporary studies suggest TCM can improve cognitive function and quality of life, there is a distinct lack of high-quality, large-scale evidence. Specifically, the relationship between TCM "syndromes" (ZHENG) and treatment efficacy, as well as the underlying biological mechanisms, remains poorly understood. The REVIEW-TCM study (REgistry for Vascular cognitive Impairment trEatment With Traditional Chinese Medicine) was designed to address these gaps by evaluating TCM in a real-world clinical setting.

Study Design and Participants

The REVIEW-TCM is a prospective, observational disease registry study. Unlike traditional randomized controlled trials (RCTs) that often have strict, narrow inclusion criteria, this registry aims to capture the diversity of real-world clinical practice. By observing how TCM is naturally integrated into patient care, researchers can gain insights into the effectiveness and safety of various herbal formulas and combination therapies.

The study aims to recruit 1,000 patients from the Hunan Hospital of Integrated Traditional Chinese and Western Medicine. The recruitment period spans from late 2022 through the end of 2027.

Detailed inclusion and exclusion criteria for the REVIEW-TCM study.

As shown in the recruitment protocol, participants must be at least 18 years old and meet specific diagnostic thresholds, including a Montreal Cognitive Assessment (MoCA) score below 26 and a Hachinski Ischemic Score (HIS) greater than 6. The exclusion criteria are comprehensive, ensuring that cognitive impairment is primarily vascular in origin rather than due to neurodegenerative diseases like Alzheimer's or Parkinson's.

Intervention and Methodology

A defining feature of the REVIEW-TCM study is its flexible approach to intervention. There are no strict limitations placed on the specific TCM treatments administered, reflecting the personalized nature of traditional practice.

Overview of the intervention strategy, focusing on TCM formulations and concomitant Western medications.

Researchers will meticulously document the details of TCM prescriptions, including specific herbs, formulations (such as Chinese patent medicines or decoctions), treatment duration, and patient compliance. Concomitant Western treatments, such as donepezil or memantine, are permitted and will be recorded to analyze potential synergistic effects.

The study employs a mixed-methods embedded design. This approach combines quantitative data—such as clinical rating scales and biological markers—with qualitative data derived from in-depth interviews with patients and their caregivers. This dual focus allows the study to capture patient-reported outcomes (PROs) that traditional cognitive tests might overlook, such as changes in emotional well-being or the perceived burden on the family.

Data Collection and Outcomes

Data is managed through a centralized electronic data capture (EDC) system to ensure accuracy and completeness. The primary outcome measure is the change in MoCA scores from baseline to 12 and 24 months. Secondary outcomes include:

  • Cognitive Domains: Executive function (Trail Making Tests) and language (Boston Naming Test).
  • Daily Functioning: Instrumental Activities of Daily Living (IADL).
  • Biological Markers: Neuroimaging (Diffusion Tensor Imaging) to assess white matter integrity and biomarkers like Neurofilament Light Chain (NFL) and Vascular Endothelial Growth Factor (VEGF).
  • Caregiver Impact: The Zarit Burden Interview (ZBI) will assess the stress levels of those caring for VCI patients.

To address the inherent biases of an observational study, the researchers will utilize Propensity Score Matching (PSM). This statistical method will help create comparable groups of patients receiving TCM versus those receiving standard Western care, allowing for a more robust analysis of treatment effectiveness.

Discussion and Future Directions

The REVIEW-TCM study represents a significant step toward "precision TCM" for vascular cognitive impairment. By integrating advanced neuroimaging and biomarkers with traditional syndrome differentiation (ZHENG), the study aims to identify which patient subtypes respond best to specific herbal interventions.

While the single-center design and the observational nature of the registry present certain limitations regarding generalizability and bias, the large sample size and rigorous statistical plan provide a strong foundation for future findings. Ultimately, this registry will provide the real-world evidence needed to guide clinicians in choosing the most effective and safe TCM therapies for the diverse population of patients living with VCI.

Summary updated

Abstract

Abstract Background Vascular cognitive impairment (VCI) is one of the most common diseases among the elderly. However, few effective drugs have been approved for VCI. Traditional Chinese medicine (TCM) has been used in dementia for thousands of years. Currently, there is limited high-quality evidence for the efficacy of TCM, and the specific characteristics of its effects and the appropriate patient populations for TCM therapies remain unclear. Herein, we aim to explore the effectiveness and safety of TCM by conducting a longitudinal, patient-centered study. Methods REgistry for Vascular cognitive Impairment trEatment With Traditional Chinese Medicine (REVIEW-TCM) is a prospective, observational disease registry study. 1000 VCI patients at the Hunan Hospital of Integrated Traditional Chinese and Western Medicine will be recruited based on the following criteria: aged 18 years or older, Montreal Cognitive Assessment (MoCA) score < 26, and Hachinski Ischemic Score (HIS)≥7. There is no strict limit on the intervention, and different TCM formulas will be focused. Cognition, activity of daily living, quality of life, mental, psychology, ZHENG of TCM, and burden of caregiver will be evaluated at admission, and 6, 12, 18, and 24 months. Meanwhile, biological tests and neuroimaging examination will be applied to further explore the mechanism of TCM. Especially, a mixed-methods embedded design will be applied by adopting quantitative and qualitative studies to explore patients-reported outcomes of TCM. Finally, propensity score matching will be adopted to analyze the effectiveness of TCM. Discussion To the best of our knowledge, the REVIEW-TCM study is the first comprehensive, prospective, mixed-methods, registry-based study to evaluate TCM treatment in VCI, which will analyze the effectiveness and safety of TCM in the real world and explore population characteristics and subtypes of VCI suitable for TCM. Study registration This study was registered on www.chictr.org.cn (ChiCTR2200064756).
BibTeX
@misc{xie2023registry,
  author = {Yao Xie and Le Xie and Junlin Jiang and Ting Yao and Guo Mao and Rui Fang and Fuliang Kang and Shiliang Wang and Anchao Lin and Ying Gao and Jinwen Ge and Dahua Wu},
  title = {{Registry for vascular cognitive impairment treatment with traditional Chinese medicine (REVIEW-TCM): Rationale and design of a prospective, observational study}},
  year = {2023},
  doi = {10.1101/2023.05.24.23290492},
  howpublished = {medRxiv},
}
Figure